An open-label study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® (recombinant methyionyl human interleukin-1 receptor antagonist [r-metHuIL-1RA]) in patients with subarachnoid haemorrhage
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2015
At a glance
- Drugs Anakinra (Primary)
- Indications Subarachnoid haemorrhage
- Focus Biomarker; Pharmacokinetics
- 29 Sep 2007 New trial record.